Loading clinical trials...
Loading clinical trials...
A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Serostim®, r-hGH in the Treatment and Maintenance of Human Immunodeficiency HIV-Associated Adipose Redistribution Syndrome, or HARS
Conditions
Interventions
Placebo
Serostim® 4 mg
+1 more
Locations
31
United States
University of Alabama/Birmingham
Birmingham, Alabama, United States
CARE CLINIC - UCLA Medical Center
Los Angeles, California, United States
1401 N. Palm Canyon
Palm Springs, California, United States
Trials Unit Div of Infectious and Immunologic Diseases
Sacramento, California, United States
UCSD - AntiViral Research Center
San Diego, California, United States
University of California, San Francisco - Div. of Endocrinology
San Francisco, California, United States
Start Date
May 28, 2004
Primary Completion Date
September 28, 2005
Completion Date
September 28, 2005
Last Updated
July 20, 2018
NCT06627764
NCT03087253
NCT05996536
NCT04142047
NCT06694805
NCT05398185
Lead Sponsor
EMD Serono
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions